免疫代谢研究检查免疫细胞如何调节其代谢以保持最佳性能，已成为癌症免疫学的一个重要关注领域。该领域的最新进展凸显了新陈代谢和免疫细胞功能之间的复杂联系，强调了进一步研究的必要性。 MicroRNA (miRNA) 因其转录后调节基因表达和影响各种生物过程（包括免疫功能和癌症进展）的能力而受到关注。虽然 miRNA 在免疫代谢中的作用仍在探索中，但最近的研究表明它们对巨噬细胞、T 细胞、B 细胞和树突状细胞等免疫细胞的代谢活动有显着影响，特别是在癌症环境中。免疫细胞代谢紊乱是癌症进展的一个标志，而 miRNA 与这一过程有关。了解 miRNA 对癌症免疫细胞代谢的精确影响对于免疫治疗方法的开发至关重要。靶向 miRNA 可能具有创造突破性癌症免疫疗法的潜力，以重塑肿瘤环境并改善治疗结果。总之，认识到 miRNA 作为各种癌症免疫细胞代谢的关键调节因子，为改进癌症免疫疗法提供了广阔的前景。进一步研究 miRNA 如何影响免疫细胞代谢可以确定新的治疗靶点并促进创新癌症免疫疗法的开发。版权所有 © 2024 Khameneh、Razi、Lashanizadegan、Akbari、Sayaf、Haghani 和 Bakhtiyari。

The study of immunometabolism, which examines how immune cells regulate their metabolism to maintain optimal performance, has become an important area of focus in cancer immunology. Recent advancements in this field have highlighted the intricate connection between metabolism and immune cell function, emphasizing the need for further research. MicroRNAs (miRNAs) have gained attention for their ability to post-transcriptionally regulate gene expression and impact various biological processes, including immune function and cancer progression. While the role of miRNAs in immunometabolism is still being explored, recent studies have demonstrated their significant influence on the metabolic activity of immune cells, such as macrophages, T cells, B cells, and dendritic cells, particularly in cancer contexts. Disrupted immune cell metabolism is a hallmark of cancer progression, and miRNAs have been linked to this process. Understanding the precise impact of miRNAs on immune cell metabolism in cancer is essential for the development of immunotherapeutic approaches. Targeting miRNAs may hold potential for creating groundbreaking cancer immunotherapies to reshape the tumor environment and improve treatment outcomes. In summary, the recognition of miRNAs as key regulators of immune cell metabolism across various cancers offers promising potential for refining cancer immunotherapies. Further investigation into how miRNAs affect immune cell metabolism could identify novel therapeutic targets and lead to the development of innovative cancer immunotherapies.Copyright © 2024 Khameneh, Razi, Lashanizadegan, Akbari, Sayaf, Haghani and Bakhtiyari.